



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sheng C. Lou, et al.

Serial No.: 10/714,689

Filed: November 17, 2003

For: MOMOCLONAL ANTIBODIES TO
HUMAN IMMUNODEFICIENCY VIRUS AND
USES THEREOF

Examiner: Jeffrey S. Parkin

Group Art Unit: 1648

Attorney Docket No.: 6755USD1

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail addressed to:

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450, on:

Date of Deposit:

November 17, 2007

Sherell Brownlee-Davis 11/17/07

Sherell Brownlee-Davis

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The following information is submitted pursuant to 37 C.F.R. §§1.97 and 1.98 in accordance with Applicants' duty of disclosure under 37 C.F.R. §1.56. This submission is not an admission that the documents cited herein are prior art as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.

Applicants submit herewith Form PTO 1449 listing the references known to Applicants. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO 1449 to Applicants. Pursuant to 37 CFR 1.98(2), copies of U.S. patents and U.S. patent application publications are not provided. However, copies of all non-U.S. patent and U.S. patent application/publication references are enclosed.

01/23/2007 CHEGA1 00030017 010025 10714689
01 FC:1006 180.00 DA

This Information Disclosure Statement is submitted after the first Office Action on the merits, but before the issuance of a final action or a notice of allowance. The Commissioner is hereby authorized to charge \$200 and any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered to Deposit Account No. 01-0025.

Respectfully submitted,
Sheng C. Lou, et al.



Audrey L. Bartnicki
Registration No. 40,499
Attorney for Applicant(s)

ABBOTT LABORATORIES
Customer No. 23492
Abbott Park, IL 60064-6008
Telephone: (847) 938-3440
Facsimile: (847) 938-2623

Form PTO - 1449 (Modified)

<p>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <i>(Modified) 1449-17</i></p> <p>O P E R A T I O N S C O M M U N I C A T I O N S</p> <p>JAN 22 2007</p> <p>PATENT & TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use several sheets if necessary)</p> <p>(37 CFR 1.98 (b))</p>	<p>ATTY. DOCKET NO. 6755.US.D1</p> <p>SERIAL NO. 10/714,689</p> <p>APPLICANT(S) Sheng C. Lou, et al.</p> <p>FILING DATE November 17, 2003</p> <p>GROUP 1648</p>
---	---

U.S. PATENT DOCUMENTS

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)